Alterity Therapeutics Ltd

Alterity Therapeutics has a strong liquidity position, with a current ratio of 12.98 and cash and equivalents amounting to 33,158,640 AUD, indicating a robust ability to meet short-term obligations. The company's price-to-book ratio of 2.0 and price-to-tangible-book ratio of 2.0 suggest that the market values the company at twice its book value, which is relatively high compared to industry norms. The company's profitability is currently negative, with a return on equity of -28.65% and a return on assets of -26.39%, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. These metrics are significantly below the industry median, highlighting the challenges Alterity faces in achieving profitability. Alterity Therapeutics does not disclose specific segments or geographic regions contributing to its revenue, making it difficult to assess revenue concentration. However, the company's operations are primarily based in Australia, and it is likely that a significant portion of its revenue is generated domestically. The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current or next fiscal year. The absence of capital expenditures and the negative operating and free cash flows suggest that the company is in a development phase, relying on existing cash reserves rather than generating positive cash flows. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.0 suggests that it is not leveraging debt to finance its operations, which reduces financial risk. However, the negative net income and operating income highlight the operational risks the company faces. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company continues to focus on research and development, with no major partnerships or product launches reported in the latest financial data.